Babies made using DNA of three people in new IVF trial
The findings were hailed as a breakthrough which raises hopes that women with mutations in their mitochondrial DNA could one day have children without passing debilitating or deadly diseases on to the children.
One out of every 5,000 births is affected by mitochondrial diseases, which cannot be treated, and include symptoms such as impaired vision, diabetes and muscle wasting.
In 2015, Britain became the first country to approve an in-vitro fertilisation (IVF) technique that uses a small amount of healthy mitochondrial DNA from the egg of a donor - along with the mother's egg and father's sperm.
Some have called the result of this process "three-parent babies", though researchers have pushed back at this term because only roughly 0.1 percent of the newborn's DNA comes from the donor.
The results of the much-awaited UK trial were published in several papers in the New England Journal of Medicine.
'Important reproductive option'
Out of 22 women to undergo the treatment at the Newcastle Fertility Centre in northeast England, eight babies were born. The four boys and four girls now range from under six months to over two years old.
The amount of mutated mitochondrial DNA - which causes disease - was reduced by 95-100 percent in six of the babies, according to the research.
For the other two newborns, the amount fell by 77-88 percent, which is below the range that causes disease.
This indicates the technique was "effective in reducing transmission" of diseases between mother and child, one of the studies said.
The eight children are currently healthy, though one had a disturbance of their heart's rhythm which was successfully treated, the researchers said.
Their health will be followed up over the coming years to see if problems arise.
Nils-Goran Larsson, a Swedish reproductive expert not involved in the research, hailed the "breakthrough".
The new technique offers a "very important reproductive option" for families affected by "devastating" mitochondrial diseases, he added.
Ethical review
Mitochondrial donation remains controversial and has not been approved in many countries, including the United States and France.
Religious leaders have opposed the procedure because it involves the destruction of human embryos. Other opponents have expressed fears it could pave the way for genetically engineered "designer babies".
An ethical review carried out by the UK's independent Nuffield Council on Bioethics was "instrumental" in conducting the new research, the council's director Danielle Hamm said Wednesday.
Peter Thompson, head of the UK's Human Fertilisation and Embryology Authority which approved the procedure, said only people with a "very high risk" of passing on a mitochondrial disease would be eligible for the treatment.
Ethical concerns have also been raised over the use of mitochondrial donation for infertility in Greece and Ukraine.
French mitochondrial disease specialist Julie Stefann told AFP that "it is a question of the risk-benefit ratio: for a mitochondrial disease, the benefit is obvious".
"In the context of infertility, it has not been proven," she added.
Oxford University reproductive genetics expert Dagan Wells observed that "some scientists will be a little disappointed that so much time and effort has, so far, only led to the birth of eight children".
Among the children being closely monitored are three that showed some signs of what is known as "reversal", which is still little understood.
It is "a phenomenon where the therapy initially succeeds in producing an embryo with very few defective mitochondria, but by the time the child is born the proportion of abnormal mitochondria in its cells has significantly increased," he explained.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Business
2 days ago
- Gulf Business
Fake Dubai-inspired chocolate bar recalled in UK over safety risk
Image: FSA website A chocolate bar inspired by the viral 'Dubai chocolate' trend has been urgently recalled across the UK after it was found to pose a serious health risk to people with peanut allergies. The Noesis Schokolade Love of Dubai , a 95g chocolate bar manufactured by NOESIS SCHOKOLADE, Gida ve Unlu Mam Ltd and distributed in the UK by Black Sea Trading Ltd. The product contains undeclared peanuts, an allergen that is not listed on the label. 'We are notifying consumers and food business who have purchased Noesis Schokolade Love of Dubai chocolate that this product contains peanut, which is not mentioned on the label, making it a possible health risk to anyone with an allergy to peanuts,' the FSA said. Read: The recall applies to all lot numbers and all best-before dates of the product. The FSA has directed food businesses to 'immediately stop sales and to undertake product withdrawals, and where there have been retail sales, to undertake product recalls.' The supplier, Black Sea Trading Ltd, has been uncontactable, adding urgency to the recall effort. 'This is because the product presents a serious risk to anyone with an allergy to peanuts,' the agency added. Investigation Enforcement authorities are now working with the FSA to investigate the supply chain and ensure all affected products are removed from the market. Allergy advocacy organisations have also been informed. The FSA advises consumers: 'Don't buy this product, and if you have bought it, don't eat it, especially if you have a peanut allergy. Dispose of the product at home and get in touch with your local Trading Standards in Great Britain or Environmental Health Officers in Northern Ireland, to let them know where you purchased it.'
The National
2 days ago
- The National
Geniuses wanted: UK universities share £54m fund to lure top researchers
Twelve leading universities and research organisations have been selected to deliver a £54 million government fund to recruit world-leading researchers to the UK. The Global Talent Fund, administered by UK Research and Innovation (UKRI), aims to attract up to 80 researchers in high-priority sectors such as life sciences and digital technologies. The 12 selected universities and research institutions across Britain have secured an equal share of the fund. They are: Bath, Queen's Belfast, Birmingham, Cambridge, Cardiff, Imperial College London, Oxford, Southampton, Strathclyde and Warwick universities, as well as the John Innes Centre and MRC Laboratory of Molecular Biology. The five-year government fund, which starts in 2025/26, will cover all eligible costs with no requirement for match funding from research organisations. Visa and relocation costs for researchers and their family members will be covered by the fund. Science minister Lord Vallance said: 'Genius is not bound by geography. But the UK is one of the few places blessed with the infrastructure, skills base, world-class institutions and international ties needed to incubate brilliant ideas, and turn them into new medicines that save lives, new products that make our lives easier, and even entirely new jobs and industries. 'Bringing these innovations to life, here in Britain, will be critical to delivering this government's Plan For Change. 'My message to the bold and the brave who are advancing new ideas, wherever they are, is: our doors are open to you. 'We want to work with you, support you, and give you a home where you can make your ideas a reality we all benefit from.' Chancellor Rachel Reeves said: 'The UK is home to some of the world's best universities which are vital for attracting international top talent. 'Supported by our new Global Talent Taskforce, the Global Talent Fund will cement our position as a leading choice for the world's top researchers to make their home here, supercharging growth and delivering on our Plan For Change.'
The National
3 days ago
- The National
Babies made using DNA of three people in new IVF trial
Eight healthy babies have been born in the UK using a new IVF technique that successfully reduced their risk of inheriting genetic diseases from their mothers, the results of a world-first trial revealed on Wednesday. The findings were hailed as a breakthrough which raises hopes that women with mutations in their mitochondrial DNA could one day have children without passing debilitating or deadly diseases on to the children. One out of every 5,000 births is affected by mitochondrial diseases, which cannot be treated, and include symptoms such as impaired vision, diabetes and muscle wasting. In 2015, Britain became the first country to approve an in-vitro fertilisation (IVF) technique that uses a small amount of healthy mitochondrial DNA from the egg of a donor - along with the mother's egg and father's sperm. Some have called the result of this process "three-parent babies", though researchers have pushed back at this term because only roughly 0.1 percent of the newborn's DNA comes from the donor. The results of the much-awaited UK trial were published in several papers in the New England Journal of Medicine. 'Important reproductive option' Out of 22 women to undergo the treatment at the Newcastle Fertility Centre in northeast England, eight babies were born. The four boys and four girls now range from under six months to over two years old. The amount of mutated mitochondrial DNA - which causes disease - was reduced by 95-100 percent in six of the babies, according to the research. For the other two newborns, the amount fell by 77-88 percent, which is below the range that causes disease. This indicates the technique was "effective in reducing transmission" of diseases between mother and child, one of the studies said. The eight children are currently healthy, though one had a disturbance of their heart's rhythm which was successfully treated, the researchers said. Their health will be followed up over the coming years to see if problems arise. Nils-Goran Larsson, a Swedish reproductive expert not involved in the research, hailed the "breakthrough". The new technique offers a "very important reproductive option" for families affected by "devastating" mitochondrial diseases, he added. Ethical review Mitochondrial donation remains controversial and has not been approved in many countries, including the United States and France. Religious leaders have opposed the procedure because it involves the destruction of human embryos. Other opponents have expressed fears it could pave the way for genetically engineered "designer babies". An ethical review carried out by the UK's independent Nuffield Council on Bioethics was "instrumental" in conducting the new research, the council's director Danielle Hamm said Wednesday. Peter Thompson, head of the UK's Human Fertilisation and Embryology Authority which approved the procedure, said only people with a "very high risk" of passing on a mitochondrial disease would be eligible for the treatment. Ethical concerns have also been raised over the use of mitochondrial donation for infertility in Greece and Ukraine. French mitochondrial disease specialist Julie Stefann told AFP that "it is a question of the risk-benefit ratio: for a mitochondrial disease, the benefit is obvious". "In the context of infertility, it has not been proven," she added. Oxford University reproductive genetics expert Dagan Wells observed that "some scientists will be a little disappointed that so much time and effort has, so far, only led to the birth of eight children". Among the children being closely monitored are three that showed some signs of what is known as "reversal", which is still little understood. It is "a phenomenon where the therapy initially succeeds in producing an embryo with very few defective mitochondria, but by the time the child is born the proportion of abnormal mitochondria in its cells has significantly increased," he explained.
